Sign in

CIK 0001754068

  • Non-accelerated filer
  • Smaller reporting company

Kalaris Therapeutics, Inc.

Sign in to watch
Ticker
KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831971007
Phone
+1 650-249-2727
Business address
400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Former names
Allovir, Inc., ViraCyte, Inc.
  1. 4 Derivatives Options or other derivatives
  2. 4 Grant or award Director acquired 11,444,503 shares (grant or award)
  3. 4 Derivatives Options or other derivatives
  4. 3 Insider Initial Statement of Ownership
  5. 3 Insider Initial Statement of Ownership
  6. 3 Insider Initial Statement of Ownership
  7. 3 Insider Initial Statement of Ownership
  8. 3 Insider Initial Statement of Ownership
  9. 3 Insider Initial Statement of Ownership
  10. 3 Insider Initial Statement of Ownership
  11. 4 Open-market sale Sinha Vikas sold 303 shares at $10.08 ($3,053)
  12. 4 Open-market sale Chief Accounting Officer sold 96 shares at $10.08 ($967)
  13. 4 Open-market sale General Counsel sold 106 shares at $10.08 ($1,068)
  14. 4 Open-market sale General Counsel sold 52 shares at an average $9.50 ($494)
  15. 4 Open-market sale Chief Accounting Officer sold 36 shares at an average $9.51 ($342)
  16. 4 Open-market sale Sinha Vikas sold 129 shares at an average $9.50 ($1,226)
  17. 4 Open-market sale General Counsel sold 409 shares at $0.44 ($180)
  18. 4 Open-market sale Chief Accounting Officer sold 332 shares at $0.44 ($146)
  19. 4 Open-market sale Sinha Vikas sold 979 shares at $0.44 ($431)
  20. 4 Gift General Counsel gave 57,549 shares (gift)

Page 3 of 19 · 363 filings